Key facts
- This page summarizes Vivek Ramaswamy's Form 4 filing for Roivant Sciences Ltd. (ROIV).
- 12 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 15 Dec 2025, 21:34.
Vivek Ramaswamy - 11 Dec 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ROIV
- Reported as of
- 11 Dec 2025
- Net transaction value
- -$67,915,416
- SEC form
- 4
- Accepted by SEC
- 15 Dec 2025, 21:34:54 UTC
- Prior SEC filing
- 17 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vivek Ramaswamy filed Form 4 for Roivant Sciences Ltd. (ROIV) on 15 Dec 2025.
Change
- Previous filing in this sequence was filed on 17 Nov 2025.
- Current net transaction value: -$67,915,416.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001635075
Primary reporting owner
Ramaswamy Vivek
- Relationship
- 10%+ Owner
- Address
- C/O STEVE ROBERTS, 700 PENNSYLVANIA AVE., SE STE. 440, WASHINGTON
- Signature
- /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy
- Signature date
- 15 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $23,707,682
- Shares
- +1,869,691
- Change %
- +5.6%
- Price
- $12.68
- Shares after
- 35,523,447
- Date
- 11 Dec 2025
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $16,752,433
- Shares
- -774,142
- Change %
- -2.2%
- Price
- $21.64
- Shares after
- 34,749,305
- Date
- 11 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
ROIV
transaction
Common Shares
Other
- Transaction value
- $23,707,702
- Shares
- -1,095,550
- Change %
- -3.2%
- Price
- $21.64
- Shares after
- 33,653,755
- Date
- 11 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $59,250,140
- Shares
- +4,672,724
- Change %
- +14%
- Price
- $12.68
- Shares after
- 38,326,479
- Date
- 12 Dec 2025
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $43,389,842
- Shares
- -1,975,858
- Change %
- -5.2%
- Price
- $21.96
- Shares after
- 36,350,621
- Date
- 12 Dec 2025
- Ownership
- Direct
- Footnotes
- F3
ROIV
transaction
Common Shares
Other
- Transaction value
- $59,223,177
- Shares
- -2,696,866
- Change %
- -7.4%
- Price
- $21.96
- Shares after
- 33,653,755
- Date
- 12 Dec 2025
- Ownership
- Direct
- Footnotes
- F2, F3
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $10,555,504
- Shares
- +832,453
- Change %
- +2.5%
- Price
- $12.68
- Shares after
- 34,486,208
- Date
- 15 Dec 2025
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $7,800,077
- Shares
- -353,745
- Change %
- -1%
- Price
- $22.05
- Shares after
- 34,132,463
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F4
ROIV
transaction
Common Shares
Other
- Transaction value
- $10,555,511
- Shares
- -478,708
- Change %
- -1.4%
- Price
- $22.05
- Shares after
- 33,653,755
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F2, F4
ROIV
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,357,857
- Date
- 11 Dec 2025
- Ownership
- Spousal
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,869,691
- Change %
- -6.3%
- Price
- $0.000000
- Shares after
- 27,655,404
- Date
- 11 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,869,691
- Exercise price
- $12.68
- Footnotes
- F6, F7
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,672,724
- Change %
- -17%
- Price
- $0.000000
- Shares after
- 22,982,680
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,672,724
- Exercise price
- $12.68
- Footnotes
- F6, F7
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -832,453
- Change %
- -3.6%
- Price
- $0.000000
- Shares after
- 22,150,227
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 832,453
- Exercise price
- $12.68
- Footnotes
- F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
Footnote F2
Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive.
Footnote F5
Represents the quantity of shares held indirectly only.
Footnote F6
Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Footnote F7
All options exercised by the reporting person would have expired in March 2026 if not exercised.